Update on pharmacologic therapy for pulmonary embolism

Prakash Harikrishnan, Chandrasekar Palaniswamy, Wilbert S. Aronow

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Warfarin, unfractionated heparin (UFH), and low-molecular-weight heparins are anticoagulants that have been used for treatment of pulmonary embolism. Currently approved drugs for treatment of venous thromboembolism include UFH, enoxaparin, dalteparin, fondaparinux, warfarin, and rivaroxaban. The advent of newer oral anticoagulants such as rivaroxaban, dabigatran, and apixaban has provided us with alternative therapeutic options for long-term anticoagulation. This article will give an overview of the various anticoagulant drugs, use in various clinical scenarios, data supporting their clinical use, and recommendations regarding duration of anticoagulant therapy.

Original languageEnglish (US)
Pages (from-to)159-169
Number of pages11
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Issue number2
StatePublished - Mar 1 2014
Externally publishedYes


  • apixaban
  • dabigatran
  • pulmonary embolism
  • rivaroxaban
  • warfarin

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)


Dive into the research topics of 'Update on pharmacologic therapy for pulmonary embolism'. Together they form a unique fingerprint.

Cite this